NO20025343D0 - Procedure for Inhibiting Proliferation and for Inducing Apoptosis in Cancer Cells - Google Patents

Procedure for Inhibiting Proliferation and for Inducing Apoptosis in Cancer Cells

Info

Publication number
NO20025343D0
NO20025343D0 NO20025343A NO20025343A NO20025343D0 NO 20025343 D0 NO20025343 D0 NO 20025343D0 NO 20025343 A NO20025343 A NO 20025343A NO 20025343 A NO20025343 A NO 20025343A NO 20025343 D0 NO20025343 D0 NO 20025343D0
Authority
NO
Norway
Prior art keywords
procedure
cancer cells
inducing apoptosis
inhibiting proliferation
proliferation
Prior art date
Application number
NO20025343A
Other languages
Norwegian (no)
Other versions
NO20025343L (en
Inventor
Thomas E Adrian
Original Assignee
Univ Creighton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Creighton filed Critical Univ Creighton
Publication of NO20025343D0 publication Critical patent/NO20025343D0/en
Publication of NO20025343L publication Critical patent/NO20025343L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20025343A 2000-05-09 2002-11-07 A method for inhibiting proliferation and for inducing apoptosis in cancer cells NO20025343L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21934400P 2000-05-09 2000-05-09
PCT/US2001/040697 WO2001085166A1 (en) 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
NO20025343D0 true NO20025343D0 (en) 2002-11-07
NO20025343L NO20025343L (en) 2003-01-09

Family

ID=22818912

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025343A NO20025343L (en) 2000-05-09 2002-11-07 A method for inhibiting proliferation and for inducing apoptosis in cancer cells

Country Status (11)

Country Link
EP (1) EP1326605A4 (en)
JP (1) JP2003532675A (en)
KR (1) KR20030019372A (en)
CN (1) CN1237968C (en)
AU (1) AU2001261832A1 (en)
BR (1) BR0110473A (en)
CA (1) CA2408622A1 (en)
MX (1) MXPA02010974A (en)
NO (1) NO20025343L (en)
NZ (1) NZ522387A (en)
WO (1) WO2001085166A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
EP2034022A1 (en) * 2007-09-10 2009-03-11 Universite Libre De Bruxelles Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
JP2015509917A (en) 2012-01-10 2015-04-02 イーライ リリー アンド カンパニー Leukotriene B4 antagonist compound
EP2990056A4 (en) * 2013-04-22 2016-12-14 Tochigi Inst Of Clinical Pathology Antitumor agent
EP3083564B1 (en) 2013-12-20 2018-07-11 Novartis AG Heteroaryl butanoic acid derivatives as lta4h inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
CA2198752A1 (en) * 1994-08-31 1996-03-07 Jason Scott Sawyer Methods for identifying and treating resistant tumors
HUP9904672A2 (en) * 1997-03-21 2000-05-28 Eli Lilly And Co. Leukotriene antagonists for oral squamous cell carcinoma
EP1231939A2 (en) * 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU1916601A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
EA200200545A1 (en) * 1999-11-11 2002-12-26 Эли Лилли Энд Компани ONCOLYTIC COMBINATIONS FOR CANCER TREATMENT
AU1916501A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Also Published As

Publication number Publication date
AU2001261832A1 (en) 2001-11-20
CN1237968C (en) 2006-01-25
CA2408622A1 (en) 2001-11-15
NZ522387A (en) 2003-09-26
MXPA02010974A (en) 2004-09-06
EP1326605A4 (en) 2004-03-17
CN1429111A (en) 2003-07-09
NO20025343L (en) 2003-01-09
JP2003532675A (en) 2003-11-05
KR20030019372A (en) 2003-03-06
BR0110473A (en) 2003-04-01
EP1326605A1 (en) 2003-07-16
WO2001085166A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
NO20014897L (en) Method for inducing cancer cell death and tumor regression
DK1355566T3 (en) Local regional chemotherapy and radiotherapy using hydrogel in situ
ITMI990375A1 (en) CO HEPOTYLON CANCER TREATMENT
NO20022656L (en) Caspase Inhibitors and Their Use
DE60138611D1 (en) SYNERGISTIC COMBINATION THERAPY FOR CANCER TREATMENT
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EE04528B1 (en) Aralam laminates for use in therapy for spirofurop ridins
NO20020343D0 (en) Caspase inhibitors and their use
NO20014560D0 (en) Quinasolines and their therapeutic use
EP1596855A4 (en) Methods and compositions for use in treating cancer
NO20005190L (en) Therapeutic angiogenic factors and methods for their use
NO20011132D0 (en) Procedure for introducing apoptosis in cancer cells
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2003235470A8 (en) Predictive markers in cancer therapy
ATE260248T1 (en) CELL PROLIFERATION INHIBITORS
AU2003258061A8 (en) Therapeutic inhibitionof protein kinases in cancer cells
AR028476A1 (en) CANCER TREATMENT
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
AU1186202A (en) Methods of inducing cancer cell death and tumor regression
AU2002308522A8 (en) Methods for inhibiting tumor cell proliferation
DK1694364T3 (en) BREAST CANCER TREATMENT AND PREVENTION SYSTEM
NO20025343D0 (en) Procedure for Inhibiting Proliferation and for Inducing Apoptosis in Cancer Cells
IS5713A (en) Mixtures of protein-farnesyl transfer enzyme and HMG COA reducing enzyme inhibitors and their use in the treatment of cancer
DE60042606D1 (en) ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER TREATMENT
HK1048599A1 (en) Cancer cell implantation inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application